Revenue from pharma business grew by 3% YoY. Notably, the segment recorded its highest therapies i.e. antihypertensive, cardiovascular, oncology and corticosteroids etc. The company also has a strong pipeline of approvals and visibility to maintain growth momentum. Segmental EBIT grew by 20% YoY in 3QFY20, and we expect similar growth in 4QFY20E as well. Specialty Chemical Biz Slight Decline in Margin...